MedPath

3,3'-diindolylmethane

Generic Name
3,3'-diindolylmethane
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C17H14N2
CAS Number
1968-05-4
Unique Ingredient Identifier
SSZ9HQT61Z
Background

Diindolylmethane has been used in trials studying the prevention and treatment of SLE, Prostate Cancer, Cervical Dysplasia, Stage I Prostate Cancer, and Stage II Prostate Cancer, among others.

Associated Conditions
-
Associated Therapies
-

Diindolylmethane in Preventing Cancer in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy, no Evidence of Disease
Interventions
Drug: diindolylmethane
Other: placebo
Other: pharmacological study
Other: laboratory biomarker analysis
Other: quality-of-life assessment
First Posted Date
2008-11-04
Last Posted Date
2016-12-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT00784394
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer

Phase 1
Completed
Conditions
Stage I Prostate Cancer
Stage II Prostate Cancer
Adenocarcinoma of the Prostate
Prostate Cancer
Interventions
Drug: diindolylmethane
Drug: placebo
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
Other: pharmacological study
First Posted Date
2007-03-22
Last Posted Date
2015-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
45
Registration Number
NCT00450229
Locations
🇺🇸

University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Diindolylmethane in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy, no Evidence of Disease
Interventions
First Posted Date
2006-10-26
Last Posted Date
2016-12-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
14
Registration Number
NCT00392652
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath